Quantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassay

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Khan, Shaukat A ^a   Joyce, Jennifer ^a   Tsuda, Takeshi ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

ioassay; Biomarker; Enzyme linked immunosorbent assay (ELISA); Mink lung epithelial cells; Myocardial infarction; Plasminogen activator inhibitor 1; Transforming growth factor (TGF ); Ventricular remodeling

Indexed keywords

ANIMALIA; MUSTELA;

LUCIFERASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ARTICLE; BIOASSAY; BIOSYNTHESIS; BLOOD; CALIBRATION; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; GENETIC TRANSFECTION; GENETICS; HEART INFARCTION; HEART MUSCLE; KIDNEY; LIVER; LUNG; METABOLISM; MINK; MOUSE; PATHOLOGY; REPORTER GENE; SENSITIVITY AND SPECIFICITY; STANDARD;

ANIMALS; BIOLOGICAL ASSAY; CALIBRATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITHELIAL CELLS; GENES, REPORTER; KIDNEY; LIVER; LUCIFERASES; LUNG; MICE; MINK; MYOCARDIAL INFARCTION; MYOCARDIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; SENSITIVITY AND SPECIFICITY; TRANSFECTION; TRANSFORMING GROWTH FACTOR BETA;

MLCS; MLOWN;

EID: 84868694221     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-636     Document Type: Article

References (43)

1. Mammalian transforming growth factor-betas: Smad signaling and physio-pathological roles. Javelaud D, Mauviel A, Int J Biochem Cell Biol 2004 36 1161 1165 10.1016/S1357-2725(03)00255-3 15109563 (Pubitemid 38515657)
2. TGF-beta signaling and the fibrotic response. Leask A, Abraham DJ, FASEB J 2004 18 816 827 10.1096/fj.03-1273rev 15117886 (Pubitemid 38544500)
3. TGF-beta signal transduction. Massague J, Annu Rev Biochem 1998 67 753 791 10.1146/annurev.biochem.67.1.753 9759503 (Pubitemid 28411144)
4. Smad transcription factors. Massague J, Seoane J, Wotton D, Genes Dev 2005 19 2783 2810 10.1101/gad.1350705 16322555 (Pubitemid 41739965)
5. TGF-beta: a balancing act. McCartney-Francis NL, Frazier-Jessen M, Wahl SM, Int Rev Immunol 1998 16 553 580 9646177
6. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Moustakas A, Pardali K, Gaal A, Heldin CH, Immunol Lett 2002 82 85 91 10.1016/S0165-2478(02)00023-8 12008039 (Pubitemid 34468039)
7. TGF-beta signaling in vascular fibrosis. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J, Cardiovasc Res 2007 74 196 206 10.1016/j.cardiores.2007.02.008 17376414 (Pubitemid 46517510)
8. Targeting transforming growth factor-beta signaling. Pennison M, Pasche B, Curr Opin Oncol 2007 19 579 585 10.1097/CCO.0b013e3282f0ad0e 17906455 (Pubitemid 47508864)
9. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Verrecchia F, Mauviel A, Curr Rheumatol Rep 2002 4 143 149 10.1007/s11926-002-0010-4 11890880
10. Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Khan R, Sheppard R, Immunology 2006 118 10 24 10.1111/j.1365-2567.2006.02336.x 16630019
11. The dynamic roles of TGF-β in cancer. Meulmeester E, Ten Dijke P, J Pathol 2011 223 205 218 20957627
12. Transforming growth factor-β and atherosclerosis: interwoven atherogenic and atheroprotective aspects. Toma I, McCaffrey TA, Cell Tissue Res 2012 347 155 175 10.1007/s00441-011-1189-3 21626289
13. Tranilast prevents the progression of chronic cyclosporine nephrotoxicity through regulation of transforming growth factor beta/Smad pathways. Tao Y, Hu L, Li S, Liu Q, Wu X, Li D, Fu P, Wei D, Luo Z, Transplant Proc 2011 43 1985 1988 10.1016/j.transproceed.2011.01.160 21693312
14. TGF-beta-dependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, Bedja D, Gabrielson KL, Hausladen JM, Mecham RP, Judge DP, Dietz HC, J Clin Invest 2004 114 1586 1592 15546004 (Pubitemid 40385549)
15. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, Verheijen JH, Hommes DW, Lamers CB, Sier CF, Br J Cancer 2007 97 398 404 10.1038/sj.bjc.6603877 17637685 (Pubitemid 47196749)
16. Determination of TGFbeta1 protein level in human primary breast cancers and its relationship with survival. Desruisseau S, Palmari J, Giusti C, Romain S, Martin PM, Berthois Y, Br J Cancer 2006 94 239 246 10.1038/sj.bjc.6602920 16404434 (Pubitemid 43151542)
17. An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB, Anal Biochem 1994 216 276 284 10.1006/abio.1994.1042 8179182 (Pubitemid 24076008)
18. Quantification of transforming growth factor-beta in biological material using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. van Waarde MA, van Assen AJ, Kampinga HH, Konings AW, Vujaskovic Z, Anal Biochem 1997 247 45 51 10.1006/abio.1997.2026 9126369 (Pubitemid 27161491)
19. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Grainger DJ, Mosedale DE, Metcalfe JC, Weissberg PL, Kemp PR, Clin Chim Acta 1995 235 11 31 10.1016/0009-8981(94)05995-4 7634487
20. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A, Nat Med 1995 1 74 79 10.1038/nm0195-74 7584958
21. Methods for measuring TGF-β using antibodies, cells, and mice. Jurukovski V, Dabovic B, Todorovic V, Chen Y, Rifkin DB, Fibrosis Research: Methods and Protocols. Volume 117 Towata: Humana Press, Varga JB DA, Phan SH, 2005 161 175
22. Post-ischemic myocardial fibrosis occurs independent of hemodynamic changes. Tsuda T, Gao E, Evangelisti L, Markova D, Ma X, Chu ML, Cardiovasc Res 2003 59 926 933 10.1016/S0008-6363(03)00519-4 14553832 (Pubitemid 38366248)
23. Measurement of protein using bicinchoninic acid. Smith PK, Krohn RI, Hermanson GT, Mallia AK, Gartner FH, Provenzano MD, Fujimoto EK, Goeke NM, Olson BJ, Klenk DC, Anal Biochem 1985 150 76 85 10.1016/0003-2697(85)90442-7 3843705 (Pubitemid 16258399)
24. Latent transforming growth factor-beta in serum. A specific complex with alpha 2-macroglobulin. O'Connor-McCourt MD, Wakefield LM, J Biol Chem 1987 262 14090 14099 2443501 (Pubitemid 17152093)
25. Transforming growth factor-beta activity is potentiated by heparin via dissociation of the transforming growth factor-beta/alpha 2-macroglobulin inactive complex. McCaffrey TA, Falcone DJ, Brayton CF, Agarwal LA, Welt FG, Weksler BB, J Cell Biol 1989 109 441 448 10.1083/jcb.109.1.441 2473082 (Pubitemid 19180150)
26. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Bujak M, Frangogiannis NG, Cardiovasc Res 2007 74 184 195 10.1016/j.cardiores.2006.10.002 17109837 (Pubitemid 46517504)
27. Identification of regulatory sequences in the type 1 plasminogen activator inhibitor gene responsive to transforming growth factor beta. Keeton MR, Curriden SA, van Zonneveld AJ, Loskutoff DJ, J Biol Chem 1991 266 23048 23052 1744101 (Pubitemid 21908758)
28. Physicochemical activation of recombinant latent transforming growth factor-beta's 1, 2, and 3. Brown PD, Wakefield LM, Levinson AD, Sporn MB, Growth Factors 1990 3 35 43 10.3109/08977199009037500 2200452 (Pubitemid 20265013)
29. Latent transforming growth factor beta1 activation in situ: quantitative and functional evidence after low-dose gamma-irradiation. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH, FASEB J 1997 11 991 1002 9337152 (Pubitemid 27425901)
30. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Sanderson N, Factor V, Nagy P, Kopp J, Kondaiah P, Wakefield L, Roberts AB, Sporn MB, Thorgeirsson SS, Proc Natl Acad Sci USA 1995 92 2572 2576 10.1073/pnas.92.7.2572 7708687
31. Interaction between angiotensin II and Smad proteins in fibroblasts in failing heart and in vitro. Hao J, Wang B, Jones SC, Jassal DS, Dixon IM, Am J Physiol Heart Circ Physiol 2000 279 3020 H3030 11087260
32. Statins inhibit angiotensin II/Smad pathway and related vascular fibrosis, by a TGF-β-independent process. Rodrigues Diez R, Rodrigues-Diez R, Lavoz C, Rayego-Mateos S, Civantos E, Rodriguez-Vita J, Mezzano S, Ortiz A, Egido J, Ruiz-Ortega M, PLoS One 2010 5 14145 10.1371/journal.pone.0014145 21152444
33. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Wang W, Huang XR, Canlas E, Oka K, Truong LD, Deng C, Bhowmick NA, Ju W, Bottinger EP, Lan HY, Circ Res 2006 98 1032 1039 10.1161/01.RES.0000218782.52610.dc 16556868
34. Transforming growth factor beta-1 in rectal tumour, mucosa and plasma in relation to radiotherapy and clinical outcome in rectal cancer patients. Angenete E, Langenskiold M, Palmgren I, Falk P, Oresland T, Ivarsson ML, Int J Colorectal Dis 2007 22 1331 1338 10.1007/s00384-007-0342-7 17657504 (Pubitemid 47456718)
35. The TGF-beta-pseudoreceptor BAMBI is strongly expressed in COPD lungs and regulated by nontypeable Haemophilus influenzae. Dromann D, Rupp J, Rohmann K, Osbahr S, Ulmer AJ, Marwitz S, Roschmann K, Abdullah M, Schultz H, Vollmer E, Zabel P, Dalhoff K, Goldmann T, Respir Res 2010 11 67 10.1186/1465-9921-11-67 20513241
36. Inhibition of progression of heart failure and expression of TGF-beta 1 mRNA in rats with heart failure by the ACE inhibitor quinapril. Ma M, Watanabe K, Wahed MI, Inoue M, Sekiguchi T, Kouda T, Ohta Y, Nakazawa M, Yoshida Y, Yamamoto T, Hanawa H, Kodama M, Fuse K, Aizawa Y, J Cardiovasc Pharmacol 2001 38 Suppl 1 51 54
37. Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure. Behnes M, Hoffmann U, Lang S, Weiss C, Ahmad-Nejad P, Neumaier M, Borggrefe M, Brueckmann M, Clin Res Cardiol 2011 100 335 342 10.1007/s00392-010-0248-1 21069358
38. Targeting endoglin, an auxiliary TGF-β coreceptor, to prevent fibrosis and heart failure. Benjamin IJ, Circulation 2012 125 2689 2691 10.1161/CIRCULATIONAHA.112.108282 22592899
39. Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. Wakefield LM, Winokur TS, Hollands RS, Christopherson K, Levinson AD, Sporn MB, J Clin Invest 1990 86 1976 1984 10.1172/JCI114932 2254455
40. Relationship between CCL5 and transforming growth factor-β1 (TGFbeta1) in breast cancer. Hartmann MC, Dwyer RM, Costello M, Potter SM, Curran C, Hennessy E, Newell J, Griffin DG, Kerin MJ, Eur J Cancer 2011 47 1669 1675 10.1016/j.ejca.2011.05.001 21658938
41. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM, Am J Transl Res 2010 2 356 367 20733946
42. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, Wu XH, Yao DB, Meng XY, Hepatobiliary Pancreat Dis Int 2008 7 288 295 18522884 (Pubitemid 351895389)
43. Transforming growth factor-beta(1) expression in dilated cardiomyopathy. Sanderson JE, Lai KB, Shum IO, Wei S, Chow LT, Heart 2001 86 701 708 10.1136/heart.86.6.701 11711472